These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32460856)

  • 1. Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study.
    Mané C; Delmas C; Porterie J; Jourdan G; Verwaerde P; Marcheix B; Concordet D; Georges B; Ruiz S; Gandia P
    J Transl Med; 2020 May; 18(1):213. PubMed ID: 32460856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxygenator Impact on Ceftolozane and Tazobactam in Extracorporeal Membrane Oxygenation Circuits.
    Cies JJ; Moore WS; Giliam N; Low T; Enache A; Chopra A
    Pediatr Crit Care Med; 2020 Mar; 21(3):276-282. PubMed ID: 31688715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the extracorporeal membrane oxygenation circuit on plasma levels of ceftolozane.
    Argudo E; Riera J; Luque S; Los-Arcos I; López-Meseguer M; Sandiumenge A; Nuvials X; Grau S; Ferrer R
    Perfusion; 2020 Apr; 35(3):267-270. PubMed ID: 31387460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance.
    Nicolau DP; De Waele J; Kuti JL; Caro L; Larson KB; Yu B; Gadzicki E; Zeng Z; Rhee EG; Rizk ML
    Int J Antimicrob Agents; 2021 Apr; 57(4):106299. PubMed ID: 33567333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
    Gatti M; Giannella M; Raschi E; Viale P; De Ponti F
    J Antimicrob Chemother; 2021 Jan; 76(1):199-205. PubMed ID: 33057628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
    Larson KB; Patel YT; Willavize S; Bradley JS; Rhee EG; Caro L; Rizk ML
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation.
    Sinnah F; Shekar K; Abdul-Aziz MH; Buscher H; Diab SD; Fisquet S; Fung YL; McDonald CI; Reynolds C; Rudham S; Wallis SC; Welch S; Xie J; Fraser JF; Roberts JA;
    Crit Care Resusc; 2017 Oct; 19(Suppl 1):8-14. PubMed ID: 29084496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
    Caro L; Nicolau DP; De Waele JJ; Kuti JL; Larson KB; Gadzicki E; Yu B; Zeng Z; Adedoyin A; Rhee EG
    J Antimicrob Chemother; 2020 Jun; 75(6):1546-1553. PubMed ID: 32211756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study.
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Cho YJ; Corley A; Diehl A; Gilder E; Jakob SM; Kim HS; Levkovich BJ; Lim SY; McGuinness S; Parke R; Pellegrino V; Que YA; Reynolds C; Rudham S; Wallis SC; Welch SA; Zacharias D; Fraser JF; Shekar K; Roberts JA;
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0143821. PubMed ID: 34460303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients.
    Hahn J; Choi JH; Chang MJ
    J Clin Pharm Ther; 2017 Dec; 42(6):661-671. PubMed ID: 28948652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study.
    Donadello K; Antonucci E; Cristallini S; Roberts JA; Beumier M; Scolletta S; Jacobs F; Rondelet B; de Backer D; Vincent JL; Taccone FS
    Int J Antimicrob Agents; 2015 Mar; 45(3):278-82. PubMed ID: 25542059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain.
    Sime FB; Lassig-Smith M; Starr T; Stuart J; Pandey S; Parker SL; Wallis SC; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.
    Chandorkar G; Xiao A; Mouksassi MS; Hershberger E; Krishna G
    J Clin Pharmacol; 2015 Feb; 55(2):230-9. PubMed ID: 25196976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
    Kakara M; Larson K; Feng HP; Shiomi M; Yoshitsugu H; Rizk ML
    J Infect Chemother; 2019 Mar; 25(3):182-191. PubMed ID: 30528208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy.
    Rawlins M; Cheng V; Raby E; Dyer J; Regli A; Ingram P; McWhinney BC; Ungerer JPJ; Roberts JA
    Chemotherapy; 2018; 63(4):203-206. PubMed ID: 30304718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study).
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Cho YJ; Corley A; Gilder E; Kim HS; Lim SY; McGuinness S; Parke R; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA;
    Clin Pharmacokinet; 2022 Jun; 61(6):847-856. PubMed ID: 35253107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
    Arrieta AC; Ang JY; Zhang Z; Larson KB; Yu B; Johnson MG; Rhee EG; Feng EH; Rizk ML
    Pediatr Pulmonol; 2020 Aug; 55(8):2025-2032. PubMed ID: 32421928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.